Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr;34(2):261-267.
doi: 10.1007/s12288-017-0876-y. Epub 2017 Sep 19.

Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India

Pankaj Malhotra  1 , Uday Yanamandra  2 , Alka Khadwal  1 , Gaurav Prakash  1 , Deepesh Lad  1 , Arjun D Law  3 , Harshit Khurana  4 , M U S Sachdeva  5 , Praveen Bose  5 , Reena Das  5 , Neelam Varma  5 , Subhash Varma  1
Affiliations

Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India

Pankaj Malhotra et al. Indian J Hematol Blood Transfus. 2018 Apr.

Abstract

Autologous stem cell transplantation (ASCT) is considered as standard of care in patients with multiple myeloma (MM) patients aged 65 years or younger. We analyzed data of 94 patients of plasma cell dyscrasias who underwent 95 autologous transplants at our institute from October 2003 to Aug 2016. Other than 76 patients of newly diagnosed multiple myeloma, we also transplanted two patients of POEMS syndrome, two patients of plasma cell leukemia, three patients of concurrent light chain deposition disease, three patients of multifocal plasmacytomas, and eight patients of isolated light chain myeloma. One patient underwent transplant twice. The median age of patients was 53 years (range 21-65). The average interval between diagnosis and transplant was 10.51 ± 5.42 months. The predominant stage in the study cohort was ISS-III. IgG kappa was the commonest subtype of plasma cell dyscrasia (27.9%) followed by IgG lambda (16.27%). Renal involvement was seen in 25% patients at the time of transplantation. Following chemotherapy, 42% patients were in CR, 39% in VGPR, 5% had PR and 14% had progressive disease at the time of transplantation. All patients were conditioned with melphalan (dose 120-200 mg/m2) except for one who received an additional bortezomib for his second transplant. The mean time to neutrophil and platelet engraftment was 11.09 ± 1.82 and 12.69 ± 4.55 days respectively. Mucositis was noted in all patients (grade 3 in 37.5% patients). The median PFS (biochemical) was 55.8% and PFS (clinical) was 76.7% at 6.5 years. Thirteen percent of the transplanted patients succumbed to their illness of which three patients died within 30 days of transplant. Median OS was 76.7% at 6.5 years. ASCT is a feasible option for MM in India and the results are comparable.

Keywords: Autologous; Myeloma; Real World; Transplant; ASCT.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsAll Authors declare that they have no conflict of interest.This research is involving human participants.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
Patient residential locations who underwent transplantation at our center
Fig. 2
Fig. 2
Stem plot depicting in days. a Peri-transplant in-hospital stay. b Posttransplant in-hospital stay. c Biochemical PFS. d Clinical PFS. e Overall survival
Fig. 3
Fig. 3
Kaplan–Meier survival curves for a clinical PFS. b Biochemical PFS. c OS
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–2972. doi: 10.1182/blood-2007-10-078022. - DOI - PMC - PubMed
    1. Kumar L, Verma R, Radhakrishnan VR. Recent advances in the management of multiple myeloma. Nat Med J India. 2010;23(4):210–218. - PubMed
    1. Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987;66(1):55–62. doi: 10.1111/j.1365-2141.1987.tb06890.x. - DOI - PubMed
    1. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95(12):4008–4010. - PubMed
    1. Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91–97. doi: 10.1056/NEJM199607113350204. - DOI - PubMed

LinkOut - more resources